Instem has acquired clinical trial technology and consulting company d-wise to further accelerate life science development.
Through the deal, the key application areas would be consolidated to help customers streamline and accelerate their research and development processes.
Additionally, access to a wide range of data across the R&D continuum is set to increase the power of future in silico modelling and prediction solutions.
The d-Wise team will form a new business unit called Clinical Trial Acceleration Solutions within Instem. The new company is expected to be the foremost authority and driving force to generate, analyse and leverage the data from discovery through late-stage clinical trials.
The acquisition of d-Wise, which is part of Instem’s transformational growth strategy, will further help to provide solutions to life science organisations for enhanced data-driven decision making.
Instem CEO Phil Reason said: “The d-wise organisation is well known for its drive to transform the life sciences through open and flexible access to data.
“They act as strategic advisers to many of Instem’s existing clients and are one of the leading IT solution engineering and integration partners in the market today.
“We are extremely excited about future opportunities to leverage wider areas of data and knowledge, backed by leading technologies and services, to maximise client value in ways we and the industry have only dreamed of in the past.”
The companies have not disclosed the financial details of the transaction.
d-wise builds clinical trial analysis and data anonymisation solutions, using open-source and cloud technologies.
The company’s solutions have been designed to meet individual client needs and provide validated pathways for Cloud adoption, as well as open-source clinical analysis.
